Lotus Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7,740	6,030	1,771	1,983	1,605
Cash & Short-Term Investments	7,740	6,030	1,771	1,983	1,605
Cash Growth	28.35%	240.51%	-10.71%	23.54%	7.82%
Accounts Receivable	6,863	7,435	6,384	4,651	3,266
Other Receivables	936.56	268.54	233.13	276.24	141.56
Receivables	7,799	7,703	6,617	4,927	3,407
Inventory	9,649	3,833	3,775	3,330	3,073
Other Current Assets	1,264	531.5	489.37	420.4	247.24
Total Current Assets	26,453	18,098	12,653	10,661	8,333
Property, Plant & Equipment	7,607	3,666	3,511	3,148	2,642
Long-Term Investments	463.88	3,594	3,048	2,158	301.73
Goodwill	31,955	6,127	5,670	5,668	5,586
Other Intangible Assets	12,204	5,199	5,487	5,910	2,971
Long-Term Accounts Receivable	113.85	122.73	152.6	-	-
Long-Term Deferred Tax Assets	13,942	486.42	411.69	390.12	310.82
Long-Term Deferred Charges	13,119	2,639	1,878	1,406	891.98
Other Long-Term Assets	295.86	168.74	180.28	185.33	185.35
Total Assets	106,154	40,101	32,992	29,526	21,222
Accounts Payable	2,416	1,070	670.8	1,403	747.55
Accrued Expenses	2,850	-	3.06	3.57	0.93
Short-Term Debt	1,609	1,615	510	155.92	1,377
Current Portion of Long-Term Debt	2,541	3,390	1,303	59.95	794.9
Current Portion of Leases	159.63	84.32	70.24	58.99	62.47
Current Income Taxes Payable	1,416	664.47	436.56	731.15	280.16
Current Unearned Revenue	179.16	180.9	132.85	183.08	132.01
Other Current Liabilities	5,707	1,433	1,398	3,297	931.26
Total Current Liabilities	16,879	8,438	4,524	5,893	4,326
Long-Term Debt	42,447	8,384	9,519	8,596	4,667
Long-Term Leases	718.62	194.06	182.2	46.82	43.41
Long-Term Unearned Revenue	16.29	26.56	45.33	65.92	85.96
Pension & Post-Retirement Benefits	767.52	673.52	503.28	371.91	502.7
Long-Term Deferred Tax Liabilities	1,697	1,093	721.2	448.4	304.15
Other Long-Term Liabilities	19,848	112.17	162.29	235.84	224.03
Total Liabilities	82,374	18,921	15,658	15,658	10,153
Common Stock	2,669	2,659	2,650	2,626	2,628
Additional Paid-In Capital	7,642	7,431	7,131	7,534	8,039
Retained Earnings	15,904	12,660	8,900	4,823	1,701
Treasury Stock	-824.16	-48.39	-51.1	-57.35	-57.75
Comprehensive Income & Other	-1,610	-1,521	-1,295	-1,058	-1,241
Total Common Equity	23,780	21,180	17,334	13,868	11,069
Shareholders' Equity	23,780	21,180	17,334	13,868	11,069
Total Liabilities & Equity	106,154	40,101	32,992	29,526	21,222
Total Debt	47,476	13,667	11,585	8,918	6,944
Net Cash (Debt)	-39,736	-7,636	-9,814	-6,935	-5,339
Net Cash Per Share	-151.87	-28.99	-37.45	-26.50	-20.80
Filing Date Shares Outstanding	262.81	265.39	264.47	262.04	262.25
Total Common Shares Outstanding	262.81	265.39	264.47	262.04	262.25
Working Capital	9,574	9,660	8,129	4,768	4,007
Book Value Per Share	90.48	79.81	65.54	52.92	42.21
Tangible Book Value	-20,380	9,855	6,177	2,291	2,512
Tangible Book Value Per Share	-77.54	37.13	23.36	8.74	9.58
Land	624.65	599.33	622.55	622.31	615.49
Buildings	4,031	2,074	1,888	1,384	1,313
Machinery	3,622	1,865	1,826	1,547	1,408
Construction In Progress	657.97	706.38	639.41	1,077	675.22
Leasehold Improvements	127.33	100.15	71.01	87.87	78.26

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.